These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 37102326)

  • 1. Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients.
    Lanzafame M; Gottardi M; Guella L; Collini L; Costa G; Guella A; Vento S
    J Chemother; 2023 Nov; 35(7):623-626. PubMed ID: 37102326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of persisting SARS-CoV-2 infection in an immunocompromised patient with repeated nirmatrelvir/ritonavir courses: a case report.
    Lindahl AL; Ahava MJ; Haukipää M; Kreivi HR; Lipponen A; Kortela E
    Infect Dis (Lond); 2023 Aug; 55(8):585-589. PubMed ID: 37334428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab.
    Gentile I; Foggia M; Silvitelli M; Sardanelli A; Cattaneo L; Viceconte G
    Virol J; 2023 Dec; 20(1):301. PubMed ID: 38102675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients.
    Mikulska M; Sepulcri C; Dentone C; Magne F; Balletto E; Baldi F; Labate L; Russo C; Mirabella M; Magnasco L; Di Grazia C; Ghiggi C; Raiola AM; Giacobbe DR; Vena A; Beltramini S; Bruzzone B; Lemoli RM; Angelucci E; Bassetti M
    Clin Infect Dis; 2023 Jul; 77(2):280-286. PubMed ID: 36976301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients.
    Huygens S; Gharbharan A; Serroukh Y; Snoek B; Franken B; Oude Munnink BB; Van Hagen PM; Bogers S; Geurtsvankessel CH; Rijnders BJA
    J Antimicrob Chemother; 2023 Jul; 78(7):1644-1648. PubMed ID: 37248664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute acalculous cholecystitis following extended administration of nirmatrelvir/ritonavir for persistent SARS-CoV-2 infection.
    Ito W; Fukumori T; Asaoka N; Imakita N; Nishimura T; Furukawa R; Nishihara Y; Fujikura H; Sekine T; Yamaguchi N; Hirata Y; Miyamoto S; Kanno T; Katano H; Suzuki T; Kasahara K
    J Infect Chemother; 2024 Jul; 30(7):659-663. PubMed ID: 38184107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.
    Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R
    Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504
    [No Abstract]   [Full Text] [Related]  

  • 8. Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection.
    Pasquini Z; Toschi A; Casadei B; Pellegrini C; D'Abramo A; Vita S; Beccacece A; Bussini L; Chionsini MC; Dentale N; Cantiani A; Lazzarotto T; Bartoletti M; Nicastri E; Zinzani P; Giannella M; Viale P
    Hematol Oncol; 2023 Dec; 41(5):904-911. PubMed ID: 37452579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evaluation of risk factors for prolonged viral shedding during anti-SARS-CoV-2 monoclonal antibodies and long-term administration of antivirals in COVID-19 patients with B-cell lymphoma treated by anti-CD20 antibody.
    Maruyama S; Wada D; Kanayama S; Shimazu H; Miyano Y; Inoue A; Kashihara M; Okuda K; Saito F; Nakamori Y; Ishii K; Kuwagata Y
    BMC Infect Dis; 2024 Jul; 24(1):715. PubMed ID: 39039440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature.
    Marangoni D; Antonello RM; Coppi M; Palazzo M; Nassi L; Streva N; Povolo L; Malentacchi F; Zammarchi L; Rossolini GM; Vannucchi AM; Bartoloni A; Spinicci M
    Int J Infect Dis; 2023 Aug; 133():53-56. PubMed ID: 37150351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy.
    Ciccimarra F; Luxi N; Bellitto C; L' Abbate L; De Nardo P; Savoldi A; Yeomans A; Molokhia M; Tacconelli E; Trifirò G
    BioDrugs; 2023 Sep; 37(5):675-684. PubMed ID: 37148526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection.
    Lieber CM; Kang H-J; Sobolik EB; Sticher ZM; Ngo VL; Gewirtz AT; Kolykhalov AA; Natchus MG; Greninger AL; Suthar MS; Plemper RK
    J Virol; 2024 Sep; 98(9):e0090524. PubMed ID: 39207133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Combination of Antiviral Therapy With Neutralizing Monoclonal Antibodies for Recurrent Persistent SARS-CoV-2 Pneumonia in Patients With Lymphoma.
    Gai X; Sun X; Liu B; Yan W; Sheng Z; Zhou Q; Sun Y
    Biomed Res Int; 2024; 2024():8182887. PubMed ID: 39140001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease.
    Colaneri M; Scaglione G; Fassio F; Galli L; Lai A; Bergna A; Gabrieli A; Tarkowski M; Ventura CD; Colombo V; Cordier L; Bernasconi D; Corbellino M; Dedivitiis G; Borghetti S; Visigalli D; Sollima S; Casalini G; Rizzardini G; Gori A; Antinori S; Riva A; Schiavini M
    Virol J; 2024 Mar; 21(1):68. PubMed ID: 38509536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.
    Epling BP; Rocco JM; Boswell KL; Laidlaw E; Galindo F; Kellogg A; Das S; Roder A; Ghedin E; Kreitman A; Dewar RL; Kelly SEM; Kalish H; Rehman T; Highbarger J; Rupert A; Kocher G; Holbrook MR; Lisco A; Manion M; Koup RA; Sereti I
    Clin Infect Dis; 2023 Feb; 76(4):573-581. PubMed ID: 36200701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of nirmatrelvir/ritonavir and remdesivir as treatment for SARS-CoV-2 infection in immunocompromised patients with hematologic malignancies. Series of four cases.
    Segura Fábrega A; Pérez Catalán I; Gómez Alfaro I; García Muñoz S; Roig Martí C; Rodríguez Lozano N; Folgado Escudero S; Varea Villanueva M; Gascón Buj A; Torres García M; Reig Valero R; Ferrando Piqueres R; Usó Blasco J
    Rev Esp Quimioter; 2023 Dec; 36(6):655-657. PubMed ID: 37786958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.
    Sutanto ST; Sinto R; Pasaribu A; Shakinah S
    Acta Med Indones; 2022 Oct; 54(4):638-644. PubMed ID: 36624705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort study.
    Drysdale M; Tibble H; Patel V; Gibbons DC; Lloyd EJ; Kerr W; Macdonald C; Birch HJ; Sheikh A
    BMC Infect Dis; 2024 Jul; 24(1):670. PubMed ID: 38965495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nirmatrelvir/ritonavir as a potential treatment for prolonged SARS-CoV-2 infection in immunocompromised patients.
    Pérez Catalán I; García Muñoz S; Roig Martí C; Gómez Alfaro I; Serrano Picazo L; Torres García M; Reig Valero R; Ferrando Piqueres R; Mateu Campos L; Ramos Rincón JM; Usó Blasco J
    Rev Esp Quimioter; 2022 Dec; 35(6):589-591. PubMed ID: 36250675
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful management of persistent COVID-19 using combination antiviral therapy (nirmatrelvir/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma.
    Maruki T; Nomoto H; Iwamoto N; Yamamoto K; Kurokawa M; Iwatsuki-Horimoto K; Yamayoshi S; Suzuki Y; Kawaoka Y; Ohmagari N
    J Infect Chemother; 2024 Aug; 30(8):793-795. PubMed ID: 38242284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.